Design and Application in Delivery System of Intranasal Antidepressants

Jingying Xu 1,2, Jiangang Tao 1,2 and Jidong Wang 3*

1 School of Marxism, Yanshan University, Qinhuangdao, China, 2 Mental Health Service Center, Yanshan University, Qinhuangdao, China, 3 Applied Chemistry Key Laboratory of Hebei Province, Hebei Key Laboratory of Heavy Metal Deep-Remediation in Water and Resource Reuse, Yanshan University, Qinhuangdao, China

One of the major reasons why depressed patients fail their treatment course is the existence of the blood-brain barrier (BBB), which prevents drugs from being delivered to the central nervous system (CNS). In recent years, nasal drug delivery has achieved better systemic bioavailability and activity in low doses in antidepressant treatment. In this review, we focused on the latest strategies for delivery carriers (or formation) of intranasal antidepressants. We began this review with an overview of the nasal drug delivery systems, including nasal drug delivery route, absorption mechanism, advantages, and limitations in the nasal drug delivery route. Next, we introduced the development of nasal drug delivery devices, such as powder devices, liquid-based devices, and so on. Finally, intranasal delivery carriers of antidepressants in clinical studies, including nanogels, nanostructured lipid, liposomes nanoparticles, nanoemulsions/microemulsion, were summarized. Moreover, challenges and future perspectives on recent progress of intranasal delivery carriers in antidepressant treatments were discussed.

Keywords: intranasal route, antidepressants, delivery carrier, design and application, challenges and future perspectives

INTRODUCTION

Depression is a state of low mood and aversion to activity that can affect a person’s thoughts, behavior, feelings, physical well-being, and circadian rhythm. Depression has become the leading cause of disability worldwide and is a significant global health burden (Glahn et al., 2012). What worries us is that, although the dozens of antidepressant drugs, which are approved by the Food and Drug Administration (FDA) as shown in Table 1, have demonstrated efficacy in clinical practice, many depressed patients do not respond to the first-line pharmacological treatment and even fail following several pharmacological interventions (Oleary et al., 2015). Why is this the case? One of the major reasons patients fail in their treatment course is the existence of the blood-brain barrier (BBB), which is the bottleneck of drug delivery for the central nervous system (CNS). BBB, which is mainly composed of cerebral endothelial cells (CECs) that constitute a selective barrier covering the inner surface of cerebral capillaries, is the major site of blood–CNS exchange, maintaining the homeostasis of the CNS (Bernacki et al., 2008; Abbott et al., 2010). CECs heavily determine the BBB permeability of most circulating compounds. Efflux transmembrane proteins, expressed in endothelial cerebral cells, and particularly those from the ABT-binding cassette family, which mainly include P-glycoprotein (P-gp) and breast-cancer-resistant protein (BCRP), are included in the BBB (Bicker et al., 2014; Tang et al., 2017). The ability to cross this biological barrier has been the determining characteristic for the effectiveness of CNS drugs. To date, there are three strategies used to deliver therapeutics across the barrier.
TABLE 1 | FDA approved antidepressants.

| Classifications | Drug name | Active ingredients | FDA approved year | Formations |
|-----------------|-----------|---------------------|-------------------|------------|
| Selective serotonin reuptake inhibitors (SSRIs) | PROZAC | Fluoxetine | 1987 | Capsule |
| CELEXA | Citalopram | 2000 | Tablet |
| PAXIL | Paroxetine | 1992 | Tablet |
| VIIBRYD | Vilazodone | 2011 | Tablet |
| Serotonin norepinephrine reuptake inhibitors (SNRIs) | EFFEXOR | Venlafaxine | 1993 | Tablet |
| CYMBALTA | Duloxetine | 2004 | Tablet |
| DESVENLAFAXINE | Desvenlafaxine | 2013 | Tablet |
| FETZIMA | Levomilnacipran | 2013 | Capsule |
| Tricyclic antidepressants (TCAs) | TOFRANIL | Imipramine | 1982 | Injection |
| PAMELOR | Nortriptyline | 1982 | Solution |
| ELAVIL | Amitriptyline | 1982 | Tablet |
| Monoamine oxidase inhibitors (MAOIs) | NARDIL | Phenelzine | 1982 | Tablet |
| PARNATE | Tranylcypromine | 1985 | Tablet |
| Other | REMERON | Mirtazapine | 1997 | Tablet |
| WELLBU-TRIN | Bupropion | 2002 | Tablet |

TABLE 2 | Preparation materials for several common delivery carriers of intranasal antidepressants.

| Classifications | Common materials | Example | References |
|-----------------|-----------------|---------|------------|
| Nanogels | Lutrol F127 | Venlafaxine | Bhandwalkar and Avachat, 2013 |
| | Chitosan- glycerophosphate | Doxepin | Naik and Nair, 2014 |
| | Chitosan-Pluronic and HPMC | Tramadol HCl | Kaur et al., 2014 |
| Nanostructured lipid | Solid lipid (glyceryl monostearate) and liquid lipid (capryol PGMC) | DLX | Alam et al., 2014 |
| Liposomes | Mixture of egg phosphatidylcholine (EPC) and cholesterol (cho) | Piperine | Priprem et al., 2011 |
| Nanoparticles | Chitosan nanoparticles | Venlafaxine | Haque et al., 2012 |
| | Alginate chitosan nanoparticles (VLF AG-NPs) | Venlafaxine | Haque et al., 2014 |
| | PLGA-chitosan nanoparticles | Desvenlafaxine | Tong et al., 2017 |
| Nanoemulsions /microemulsion | Capmul MCM, Solutol HS 15, and propylene glycol | Paroxetine | Pandey et al., 2016 |
| | Capmul MCM [O-7% w/w] –TRIN | Mirtazapine | Thakkar et al., 2013 |

of the BBB (Sun et al., 2017; Aderibigbe and Naki, 2019; Saeedi et al., 2019; Zhang M. et al., 2019; Shi et al., 2020): (1) by other routes of drug delivery including drug-encapsulated wafers inserted in the tumor cavity, facial intradermal injection, and drugs administered via the nasal cavity; (2) by interrupting the BBB using surfactants and hyperosmotic agents, cell-penetrating peptides, or magnetic nanoparticle-induced hyperthermia; and (3) by endogenous transporters and receptors for enhanced neural non-invasive penetration of drugs. Although antidepressant drugs have recently been identified as substrates, inhibitors, and inducers of P-gp (Obrien et al., 2012), an effective therapy with antidepressant drugs depends on drug concentrations and bioactivity, but conventional oral and parenteral therapies are limited due to the difficulty in crossing the BBB (Vitorino et al., 2019). Nasal mucosa as a potential administration route has achieved faster and higher levels of drug absorption because more compounds could permeate and administrate due to the high permeability, high vasculature, low enzymatic environment of nasal cavity, and avoidance of the hepatic first pass metabolism (Jadhav et al., 2007; Alagusundaram et al., 2010). In recent years, nasal drug delivery has achieved better systemic bioavailability and activity in low doses because the nasal route avoids the hepatic first pass elimination associated with the oral delivery. Intranasal drug delivery proposed a reliable method to bypass the BBB. Due to a direct connection between the brain and the nasal cavity, intranasal administration is the preferred route from the outside environment. Moreover, intranasal formulations have been developed to degrade enzymatic ion and improve the pharmacological effects. More and more pharmaceutical scientists and clinicians have given increasing attention to drug delivery via the nasal route, as shown in Table 2 (Kanojia et al., 2017; Ambrus et al., 2020; Shetty et al., 2020).

In this review, we focused on the latest strategies of delivery carriers of intranasal antidepressants (Scheme 1). We began this review with an overview of the nasal drug delivery systems, including nasal drug delivery route, absorption mechanism, and advantages and limitations in nasal drug delivery route. Next, we introduced the development of nasal drug delivery devices, such as powder devices, liquid-based devices, and so on. Finally, intranasal delivery carriers of antidepressants in clinical studies, including nanogels, nanostructured lipid, liposomes
nanoparticles, and nanoemulsions/microemulsion, were summarized. Moreover, challenges and future perspectives on recent progress of intranasal delivery carriers in antidepressant treatment were discussed.

**NASAL DRUG DELIVERY SYSTEMS**

**Nasal Drug Delivery Route**

The nasal route has gained attention as it is a direct non-invasive way to transport drugs to the brain which cannot be transferred via the oral route. To date, olfactory and trigeminal nerves have been shown to be safe and effective pathways to deliver therapeutic agents to brain (Figure 1).

The olfactory pathway is composed of the olfactory epithelium, lamina propria, and olfactory bulb. Three types of cells, neuronal cells, progenitor cells, and supporting cells belong to the olfactory epithelium and are connected by tight junctions. An information pathway to the brain is built by neuronal cells which start from the olfactory bulb in the CNS to the olfactory epithelium in the nasal cavity (Leopold, 1988). Due to the constant motion between basal cells and neural cells, the delivery ability of drugs to the brain was enhanced (Caggiano et al., 1994). Lamina propria, which consists of blood vessels, mucus secreting glands, olfactory axons, and a maxillary branch of trigeminal nerve, lies on the nasal epithelium (Brand, 2006; Choi et al., 2020; He et al., 2020). The olfactory bulb is used for direct nasal delivery of drugs for its distribution in different regions of the brain, such as the piriform cortex, amygdala, and hypothalamus (Khan et al., 2017).

The trigeminal pathway is another important route for delivery of therapeutic agents to the brain. The trigeminal nerve with three branches, including the ophthalmic nerve, maxillary nerve, and mandibular nerve, control the respiratory region of the nasal cavity and sensation of the nasal cavity. Among them, ophthalmic and maxillary nerves bring the information from the nasal cavity to the CNS by controlling the nasal mucosa. So, numerous drug delivery systems for the brain or nerves usually use these two branches as a target for the delivery of drugs (Johnson et al., 2010; Veneceau et al., 2016). Drugs enter the brainstem through pons by the trigeminal nerve controlling the nasal cavity and then travel to caudal and rostral parts of brain so that transport of drugs to the brain is achieved. Because not only the olfactory pathway but also the trigeminal pathway could deliver drugs to the rostral area of the brain, it difficult to distinguish when drugs are intranasally administered to the brain by nasal administration (Thorne et al., 2004; Johnson et al., 2010) as shown in Figure 2.

Cerebrospinal fluid (CSF) in the subarachnoid space and nasal lymphatics provide a pathway for therapeutics to both CSF and other areas of the CNS (Dhuria et al., 2010). Some radiolabeled tracers were injected into the CSF in cerebral ventricles or subarachnoid space drain to olfactory bulbs, which then traveled into channels and entered the nasal lymphatic system and cervical lymph nodes (Johnston et al., 2004), which demonstrated the reach of drugs to the CNS after intranasal drugs moved from the nasal cavity to the CSF, the brain interstitial spaces, and perivascular spaces. Moreover, the distribution of neurotherapeutics in CSF also proves the mechanism of nose-to-brain drugs (During et al., 2003).

**Mechanism of Drug Nasal Delivery and Absorption**

The principal process in the delivery and absorption of a drug by the nasal cavity route is through the mucus. Mucin, which is formed from mucus, is a protein that has the potential to bind with solutes and thus affect the diffusion process. There are numerous mechanisms for nasal delivery and absorption through the mucosa, including paracellular and transcellular routes (Duvvuri et al., 2003). Paracellular transport is an inverse correlation between intranasal absorption and the molecular weight of water-soluble compounds. When a molecular weight is >1,000 Daltons, drugs showed poor bioavailability (Huang et al., 1985; Alex et al., 2014; Li Y. et al., 2018). The second mechanism is a transcellular process and is responsible for the transport of lipophilic drugs that show a rate dependency on their lipophilicity (Kangmieler et al., 2014; Proschak et al., 2017). As discussed above, to enhance bioavailability, permeation enhancers are necessary (Wang and Chow, 2014; Yamamoto et al., 2017). Permeation enhancers would induce reversible modifications on the structure of the epithelial layer by modifying the phospholipid bilayer (Dhuria et al., 2010; Mouez et al., 2014).

**Advantages and Limitations of Nasal Drug Delivery Route**

An intranasal drug delivery system offers a non-invasive, effective, reliable, direct, and alternative route to the CNS via the neural connections between the nasal mucosa and the brain (Graff and Pollack, 2005), which is one of the most permeable and highly vascularized sites for drug administration and the onset for therapeutic action (Illum, 2000; Thorne and Frey, 2001). Some distinctive advantages for drug delivery are as follows:

![Scheme 1](image-url)
Xu et al. Intranasal Antidepressants

FIGURE 1 | Pathway for brain targeting after intranasal administration.

FIGURE 2 | Intranasal administration delivers IRdye 800 to the trigeminal nerve. The trigeminal nerve (see inset) has high IRdye 800 concentrations in four locations: (1) the maxillary incisal nerve as it passes through the middle concha, (2) the infraorbital nerve as it passes through the maxillary sinus, (3) the septal branch, and (4) maxillary molar branch as they pass through the choana. The maxillary teeth and trigeminal nerve receive IRdye based on its proximity from these trigeminally connected structures. Reprinted with permission from ref. Johnson et al. (2010). Copyright (2010) American Chemical Society.

(1) A large surface for drug absorption; (2) Convenience and good patient compliance; (3) Rapid attainment of therapeutic drug levels in the blood; (4) High drug permeability, especially for lipophilic and low molecular weight drugs; (5) Avoidance of harsh environmental and gastrointestinal conditions; (6) Bypassing of the hepatic first-pass metabolism; (7) Potential direct drug delivery to the brain along the olfactory nerves; (8) Direct contact site for vaccines with lymphatic tissues; (9) Convenient for patients in long-term therapy; and (10) An alternative route for drugs with poor stability in fluids. In the nasal epithelium, the therapeutic agents are delivered to the olfactory bulb and brainstem, and disperse to other CNS areas via pulsatile flow within the perivascular spaces of cerebral blood vessels which contributes to drug absorption. It is almost equal to intravenous injections in some instances, owing to the unique direct connection between the brain and the nasal cavity (Angeli et al., 2019; Musumeci and Bonaccorso, 2019; Craft et al., 2020). Intranasal administration is the only route that connects the brain with the outside environment (Mistry et al., 2009), which has received attention due to its wide drug delivery potential, including nucleotides, peptides, proteins, and even stem cells. Moreover, the nasal route of drug delivery includes both local and systemic drug delivery. A wide range of pharmaceutical dosage forms, including solutions, gels, suspensions, emulsions, liposomes, and microparticles administered via nasal route (Fortuna et al., 2014; Kumar et al., 2016; Kashyap and Shukla, 2019; Nidhi et al., 2019; Kaneko et al., 2020; Wang et al., 2020) achieved an enhanced targeting ability and reduced systemic side-effects.

However, some vital factors and physicochemical properties influence the nasal absorption of drugs: (1) Physiochemical properties of the drug, including molecular weight, particle size, lipophilic-hydrophilic balance, and enzymatic degradation; (2) Nasal effect, including membrane permeability, environmental pH, mucociliary clearance, etc.; and (3) Delivery effect, including formulation, drugs distribution and deposition, and viscosity of the formulation (Alagusundaram et al., 2010; Chaturvedi et al., 2011; Bakri et al., 2018; Inoue et al., 2020). For example, some polar drugs or macromolecules are not absorbed in high enough concentrations for their poor membrane permeability, rapid clearance, and enzymatic degradation within the nasal cavity. And the nasal mucosa and physiological and anatomical factors, including nasal blood flow, enzymatic degradation, mucociliary clearance, the physical condition of the nose, including nasal atrophic rhinitis and severe vasomotor rhinitis, could also reduce the capacity of nasal drug absorption and bioavailability as Figure 3 (Sintov et al., 2010; Qian et al., 2014; Mansuri et al., 2016; Rohm et al., 2017; Inoue et al., 2018; Rohrer et al., 2018; Akel et al., 2020; Badhe and Nipate, 2020). These limitations must be addressed in the design of drug absorption by the nasal route.

NASAL DRUG DELIVERY DEVICES

It should be noted that efficient and novel nasal drug delivery devices used for direct transport of drugs from nose to brain is another important strategy for the improvement of diagnosis
and treatment effect, which help drugs to be transported to the brain via the olfactory/trigeminal pathway. Some devices, including droppers, syringes, pressurized meter dose inhalers, Breathe Powered Bi-directional nasal devices, and pressurized olfactory delivery devices, were adopted in clinical treatment and were also categorized into devices with liquid, powder, and semisolid formulations (Djupesland, 2013; Erdö et al., 2018). The right delivery system depended on the type of drug formulation. Powder formulations with high stability often stick to the nasal mucosa before it is cleared. Liquid formulations are the oldest, cheapest, and simplest method. Popular nasal sprays spread easily and deposit in the olfactory region. The spray would distribute in the nasal cavity through nasal mucociliary clearance. But the limitation of nasal drops or spray devices depends on the self-administration technique.

**Powder Devices**

Compared with liquid (solution or suspension) and gel formulations of drugs, powder particles are stable and not easily dissolved so they can remain in the nasal mucosa for a long time. Moreover, because of free preservatives, powder dosages could be administrated in a large dose and prevent microbial contamination. Deposition and absorption of a powder formulation of drugs for nasal delivery depend on many factors, including size and shape of powder particle, flow characteristics, and solubility (Djupesland, 2013) as shown in Figure 4.

An insufflator composed of straw or tube with drugs could directly deliver drugs to the olfactory region, although usually local anesthetics or decongestants are needed before insufflations delivery. Direct Haler, designed by a Danish company, delivered fine particles into the nasal cavity with lungs exposure. Compared with pressurized metered dose inhalers (pMDI) with poor patient acceptability, insufflators utilized the exhalation force of patients to deliver drugs in liquid or powder form on the nasal epithelium (Djupesland, 2013). The nasal valve is a barrier for delivery of drugs because the nasal cavity is narrow. Optinose, a biopharmaceutical company, proposed closed-palate Bi-Directional™ Breath Powered® DDSs, which used an exhale device to target the drug beyond this valve (Djupesland, 2013; Djupesland et al., 2014). As we know, oxytocin has already been used for treatment of patients on the autism spectrum, however, a higher dose would lead to adverse effects. Quintana et al. (2015) proposed a randomized four-way crossover trial using a breath powered optinose device to study the relationship between the effect of oxytocin on social cognition with dose. Through this device, a lower dose was observed with a breath powered optinose device to deliver oxytocin across the nasal mucosa to the brain and demonstrated that lower doses are more efficacious than higher in producing a cognitive response.

Dry powder inhalers (DPI), which contain drug particles suspended or dissolved in solvent when they contact the nasal mucosa, deliver small doses to the nasal cavity. Teijin Puvlizer Rhinocort® is the earliest dry powder inhaler on the market. Rhinocort Turbohaler®, Rhinicort Puvlizer®, and Erizas® are three popular nasal dry inhalers used for the treatment of rhinitis (Gomes dos Reis et al., 2020). Dry powder inhalers are simple in design, cheap, can be operated without medical supervision, and doses range from µg to mg.

Bespak developed Unidose-DP™, resembling Flit Lizer technology, which was composed of a sealed container used for delivering a single shot of a drug. About 95% of the drug was delivered to the nasal cavity and about 60–70% reached the nasal vestibular region (Kaye et al., 2009). Sulvent™ is a powder delivery device and forces the powder to the nasal cavity. Vaccines have been delivered through this device (Huang et al., 2004). µco™ System was designed by Shin Nippon Biomedical Laboratories for drug absorption and decreased dose requirement. Powder carriers with systemic delivery, low molecular weight, and high molecular weight enhanced safety in clinical treatment (Bell et al., 1971; Ugwoke et al., 1999). µco™ System was designed by Shin Nippon Biomedical Laboratories. The µco™ carrier technology was based on a mucosal adhesives powder drug carrier, which increased drug absorption and decreased doses of drug and provided a high activity and long contact time (Djupesland, 2013).
**Liquid-Based Devices**

Catheter-delivered drugs are the simplest method of drug delivery to the nasal cavity through the insertion of a catheter in the nose cavity. This technique is usually accompanied with anesthesia or a sedative to deliver the liquid. Because mucosa is sensitive to the deposition site, it is a major issue with this method of drug delivery. By blowing with the mouth, solution filled in the catheter enters into the nostril by the other end of the catheter in the nose cavity (Trangsrud et al., 2002; Berger et al., 2007; Djupesland, 2013).

Drops are another important method of nasal drug delivery for liquid formulations and have been used for decades due to their cost effectiveness and easy manufacture. However, this method risks microbial contamination and chemical instability. Glass droppers are a typical single dose drug delivery, and spray pumps would obtain a multidose administration. However, spray pumps are expensive and often are replaced by cheap disposable pipettes in clinical treatment. Pipettes, especially in treatment for nasal decongestion and irrigation purposes, often replace the drop or spray pump in the European market (Penttilä et al., 2000).

The olfactory epithelium is located in the upper part of the nose and is about 3–10% of the surface area of the nasal cavity between the nose and brain. It is a challenge to deliver therapeutic molecules via the nasal cavity due to its turbinate restriction (Morrison and Costanzo, 1990; Fonseca-Santos et al., 2015; Brozzetti et al., 2020). The pressurized olfactory device (POD) of Impel NeuroPharma (Seattle, Washington), containing a suitable tank, compressed air or nitrogen, chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA), used as a propellant and air chamber, was realized to target the drug to the olfactory part of the nasal cavity. POD could transport both liquid and powder formulations through the nasal epithelium. Impel NeuroPharma deliver aqueous and powder forms of cholinergic reactivator (pralidoxime, 2-PAM) by POD with a higher concentration of 2-PAM in the brain (Brunelle et al., 2012; Bachurin et al., 2018).

**INTRANASAL DELIVERY CARRIERS OF ANTIDEPRESSANTS IN CLINICAL STUDIES**

Conventionally, drugs that are administered through the intranasal route are in the forms of solutions, suspensions, gels, emulsions, and powders. However, these conventional dosage forms meet many problems, such as a lack of dose precision, high particle size, high viscosity, and lack of drug stability. To enhance patient convenience, adherence, and comfort, alternating drug formulations and routes of administration should be used. As we know, oral and injectable routes of drug delivery result in a relatively well-tolerated therapeutic management, but it isn’t feasible in all patients. The pharmacokinetic and physicochemical properties of drugs used in intranasal administration and drug properties for antidepressant medications are summarized in Table 3 (Mathias and Hussain, 2010; Bento et al., 2014). Two important factors, degree of lipophilicity (log P) and absorption of the acid dissociation constant (pKa), would most affect drug intranasal administration. Theoretically, based on these chemical properties, alternative routes of administration for antidepressants depending on different and novel formulations, including nanogels, nanostructured lipid, liposomes nanoparticles, and nanoemulsions/microemulsion,
could be explored as drug delivery systems for intranasal delivery (Joshi et al., 2006; Wong et al., 2017; Ding et al., 2019a).

**Nanostructured Lipid**

Nanostructured lipid carriers (NLCs), which are the nanostructured particles produced from the two-phased blend of solid and liquid lipids, have gained increasing attention during the last years. A characteristic feature of the NLC is its controlled “imperfections” nanostructure, which is created by lipid particle matrix as imperfectly as possible by spatially very different molecules being mixed into them. The imperfections in NLC increase drug loading capacity and minimize or avoid drug loss resulted from light, oxidation and hydrolysis. NLC has been used as a delivery carrier of therapeutic substances to the brain (Muchow et al., 2008).

Duloxetine (DLX) is the first class of anti-depressants which ensures rapid and sustained efficacy in treatment of both emotional and physical symptoms of depression. On oral administration of DLX, its bioavailability, kept about 50%, undergoes hepatic first pass metabolism (Martin et al., 2003). Moreover, as we know, the efficacy of antidepressants relies upon their continued presence at the site of action (brain), however, as DLX is an oral as well as intravenous administration, the BBB would restrict the access of antidepressant drugs to the brain, leading to the reduction in dose and side effects (Laffleur and Keckeis, 2020). Alam et al. (2014) reported a nanostructured lipid carrier system of intranasal administration in which the antidepressant drug, duloxetine (DLX), was contained to circumvent the BBB and maintain prolonged release at the site. DLX-NLC was prepared by mixing melted solid lipid (glyceryl monostearate) and liquid lipid (capryol PGMC), after which both of them were homogenized with hot surfactants aqueous solution (80°C pluronic F-68, 1.5%; sodium taurocholate, 0.5%) and lyophilized. The biodistribution studies suggested that DLX-NLC formulation had a better brain targeting efficiency and higher concentration of DLX in the brain by intranasal administration compared with the intravenous administration in the treatment of depression.

**Liposomes**

To date, two of the most popular pathways to delivery drugs via nasal administration that are also highly lipid-soluble compounds are hydrophilic and semilipophilic substances. However, highly lipid-soluble compounds usually require several steps and are relatively slow. Hydrophilic and semilipophilic substances provide a relatively quick absorption into the cerebrospinal fluid (CSF). Now liposomes have been used as an effective delivery system to the brain, due to particles being entrapped into the compounds and preventing the rapid degradation through the BBB and distribution in the brain tissue (Talegaonkar and Mishra, 2004; Krauze et al., 2006; Ding et al., 2019b). Liposomes could be prepared into nanosize vesicles (20–100 nm) by phospholipids and similar amphiphilic lipids. Lipid

---

**TABLE 3 | Physicochemical properties of intranasal antidepressants.**

| Drug           | Adult oral dose | Molecular weight of parent molecule | Log P | Basic pKα |
|----------------|-----------------|-------------------------------------|-------|-----------|
| Citalopram     | 20–40 mg        | 324.4                               | 3.72  | 9.57      |
| Desvenlafaxine | 50–100 mg       | 263.4                               | 2.80  | 9.33      |
| Doxepin        | 75–300 mg       | 279.4                               | 3.91  | 9.19      |
| Escitalopram   | 10–20 mg        | 324.4                               | 3.72  | 9.57      |
| Fluvoxamine    | 50–300 mg       | 318.3                               | 2.55  | 9.39      |
| Mirtazapine    | 15–45 mg        | 265.4                               | 3.09  | 8.1       |
| Paroxetine     | 20–50 mg        | 329.4                               | 3.23  | 9.68      |
| Selegiline     | 5–30 mg         | 187.3                               | 3.79  | 7.53      |
| Trazodone      | 50–400 mg       | 371.9                               | 2.42  | 7.52      |
| Venlafaxine    | 75–375 mg       | 277.4                               | 3.02  | 9.27      |
bilayers of liposomes are similar to membranes in living cells; thus, they can carry lipophilic substances such as drugs within these layers as cell membranes. Specially, because the drug is entrapped in liposomes, a decreased dose of a compound is usually expected (Sharma and Sharma, 1997; Druliskawa and Dandrea, 2015; Wang et al., 2016) for rapid metabolism and bypassing of the BBB. The nasal route of quercetin can serve as a potential pathway for systemic drug delivery because of the high degree of vascularization and permeability of the nasal mucosa. Priprem et al. (2008) developed intranasal quercetin liposomes and assessed the anxiolytic and cognitive effects on rats based on lipid thin film formation and extrusion. The lipid thin film was a mixture of egg phosphatidylcholine (EPC) and cholesterol (chol). Due to the semilipophilic character of quercetin, it was mixed to the EPC/chol using a vehicle (water, 50% ethanol, and 50% PEG). Quercetin liposomes showed anxiolytic and cognitive-enhancing effects. Moreover, a lower dose and a faster rate were observed with intranasal quercetin liposomes which exhibited that the intranasal quercetin liposomes were effective in the delivery of quercetin to the central nervous system. Piperine, which encapsulated liposomes for intranasal delivery, was investigated in male Wistar rats (Priprem et al., 2011). Piperine, as a major alkaloid of black long pepper, had been proven to possess various activities, including anti-inflammatory and anti-depressant (Lee et al., 2005; Menneson et al., 2020). A lipid film of EPC and chol was used in the presence of piperine and chloroform. Subsequently, piperine-encapsulated liposomes were prepared. Intranasal liposomes also proved their potential in the delivery of piperine, at a low dose, to exert its antidepressant and cognitive enhancing activities.

Nanoparticles

Among intranasal drug delivery systems, the mucoadhesive chitosan nanoparticles (NPs) possess the ability to reduce the mucociliary clearance, pass through the tight junctions of cells transiently, and provide a drug transport route from the nasal membrane to the brain by the paracellular route because of its particle size, enhanced permeability, and ability to encapsulate various ingredients (Maculotti et al., 2005; Villasaliu et al., 2010; Chen J. et al., 2020). Venlafaxine (VLF) is a dual action antidepressant [serotonin and norepinephrine reuptake inhibitors (SNRI)]. Oral therapy of VLF meets some problems, such as slow onset of action and side effects like tachycardia, increased blood pressure, fatigue, headache, dizziness, sexual dysfunction, and low bioavailability (40–45%).

Haque et al. (2012) prepared venlafaxine (VLF)-loaded chitosan nanoparticles (NPs) to enhance the uptake of VLF to the brain via intranasal delivery. One phase which contained a solution of polycation chitosan mixed with another that contained a solution of polyanion sodium tripolyphosphate (TPP) at room temperature and VLF was dissolved into chitosan solution at the drug polymer ratio of 1:1 before the addition of TPP. The brain/blood ratios of VLF for VLF (i.v.), VLF (i.n.), and VLF chitosan NPs (i.n.), were 0.0293, 0.0700, and 0.1612, respectively, at 0.5h, which indicated a better brain uptake of VLF-chitosan NPs, higher drug transport efficiency (508.59), and direct transport percentage (80.34) of VLF chitosan NPs. In another piece of research, Haque et al. (2014) investigated Venlafaxine-loaded alginate chitosan nanoparticles (VLF AG-NPs) for the treatment of depression via intranasal (i.n.) nose to brain delivery route. Pharmacodynamic studies of the VLF AG-NPs for antidepressant activity were carried out in vivo by forced swimming test, which indicated that VLF AG-NPs (i.n.) treatment significantly improved the behavioral analysis parameters including swimming, climbing, and immobility. Tong et al. (2017) prepared Desvenlafaxine-loaded PLGA-chitosan nanoparticles by solvent emulsion evaporation technique and the optimized Desvenlafaxine-loaded PLGA-chitosan nanoparticles based on intranasal administration significantly reduced the symptoms of depression. Intranasal Desvenlafaxine PLGA chitosan nanoparticles also enhanced the Desvenlafaxine in brain together with their brain/blood ratio at different time points, which demonstrated its better efficacy in treatment of depression. Singh et al. (2015) presented the study of thiolated chitosan nanoparticles (TCNs) which were synthesized by the ionic gelation method, to enhance the nasal delivery of selegiline hydrochloride for effective treatment of depression. In the evaluation of drugs on animals, selegiline hydrochloride—TCNs successfully attenuated oxidative stress and restored the activity of the mitochondrial complex. In an evaluation of behavioral parameters, TCNs successfully restored the impaired locomotor activity and normal sucrose consumption was found on treatment. TCNs seemed to be promising carriers for nose-to-brain delivery in the evaluation of antidepressant activity.

Nanoemulsions /Microemulsion

Intranasal delivery of drugs allows the drug to directly enter the brain by bypassing the BBB and avoids extensive hepatic and intestinal metabolism. This route has been a convenient and reliable route. Several new formulations are used to deliver drugs to the brain by olfactory, neuronal, and trigeminal pathways. Nanoemulsions are a promising and novel formulation to deliver lipophilic drugs to the brain through the intranasal route, which is an optically isotropic and thermodynamically stable system composed of oil, water, and surfactant (and/or co surfactant) (Mehta et al., 2008). Due to its high solubilization of lipophilic drugs, stability, ease of preparation, and handled stabilization of hydrolytically susceptible compounds, it provided the advantages of bioacceptability, biodegradability, and rapid uptake by the brain (Abouhussein et al., 2018; Pires and Santos, 2018). Many drugs, including Sumatriptan (Vyas et al., 2006a; Ganger and Schindowski, 2018), Zolmitriptan (Vyas et al., 2005; Islam et al., 2020), Cabergoline (Sharma et al., 2009; Pires and Santos, 2018), Clonazepam (Vyas et al., 2006b; Costa et al., 2019), Nimodipine (Zhang et al., 2004), Tacrine (Jogani et al., 2008), and Diazepam (Li et al., 2002), have been administered via the nasal route in...
the form of microemulsion (Mason et al., 2006; Jones et al., 2017; Singh et al., 2017; Sindhu et al., 2018). Pandey et al. (2016) developed a paroxetine-loaded nanoemulsion (o/w type) for direct nose-to-brain delivery. Nanoemulsions were constructed by the spontaneous emulsification technique using oil phase, including Capmul MCM, Solutol HS 15, and propylene glycol, surfactant and co-surfactant, for a delivery system via the nasal route to treat depression. Intranasal treatment of depressed rats with paroxetine nanoemulsion significantly improved the behavioral activities in comparison to oral paroxetine control groups. Biochemical estimation results suggested that the paroxetine-loaded nanoemulsion was effective in enhancing the depressed levels of glutathione and decreasing the elevated levels of thiobarbituric acid reactive substances (TBARS). Thakkar et al. (2013) prepared mirtazapine microemulsion for intranasal delivery microemulsions (MME-26% w/w, mirtazapine) through completely dissolving mirtazapine in a mixture of oil Capmul MCM (O-7% w/w), surfactant Tween-80 (S-33.75% w/w), co-surfactant, and Polyethylene Glycol 400 (CoS-11.25% w/w). Pharmacokinetics, swim tests, locomotor activity, maze tests, and brain/blood uptake ratios all demonstrated a more rapid and a larger extent of transport of mirtazapine into the brain with intranasal mirtazapine mucoadhesive microemulsion.

CONCLUSIONS AND PERSPECTIVES

Direct intranasal drug transportation to the brain has been highlighted as a potential strategy for addressing antidepressant therapy, because it would break through the bottleneck of the blood-brain barrier and enhance targeting ability. It is well-known that the progress of intranasal drug transportation benefits from nanocarrier-based formulations, however, although encouraging and tremendous developments have achieved, to explore and apply all kinds of drug carriers for antidepressant treatment by the intranasal route in clinics retains many challenges. Drugs in the intranasal delivery route are more sensitive for enzyme, acid, and hepatic metabolism than other routes. Moreover, the absorption and bioavailability of drugs can usually be influenced by rapid drug elimination, limited administration volume, and so on. In addition, the use of intranasal drugs is still at an early stage and far from clinical practice. As we know, esketamine nasal spray was recently approved as the first intranasal prescription medicine used for the treatment of depression. These findings corroborate that nose-to-brain drug delivery could provide a strong effective solution for treatment-resistant depression. Regulatory issues in safety and quality aspects need to be satisfied to translate these methods from research to the market. The pharmaceutical industry must be evolving and improving processes for manufacturing accurate and repeatable intranasal dose in the coming years. In this review, we introduced the absorption mechanism, advantages including large absorption surface area, good patient compliance, rapid and high drug permeability, bypassing of hepatic first-pass metabolism, potential direct drug delivery to the brain along the olfactory nerves, and limitations, including rapid drug elimination prompted by mucociliary clearance (5 mm/min for healthy humans), limited administration volume (25–200 ml), and the presence of enzymes that degrade in nasal drug delivery route (Lechanteur et al., 2017, 2019; Chen S. et al., 2020; Lechanteur and Evrard, 2020; Sabir et al., 2020; Taipaleenmaki and Stadler, 2020). Then, we systematically summarized the development of intranasal delivery carriers of antidepressants in clinical studies including nanogels, nanostructured lipid, liposomes nanoparticles, and nanoemulsions/microemulsion. Finally, recent progress, challenges, and future perspectives of intranasal delivery carriers in antidepressant treatment were discussed.

AUTHOR CONTRIBUTIONS

JX: conceptualization and writing—original draft preparation. JT: investigation and writing—original draft preparation. JW: supervision, writing—reviewing, and editing. All authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 62071413), the Hebei Natural Science Foundation (No. F2020203056), Hebei Social Science Foundation (HB16SH050), Hebei education department key project (No. ZD2020147), and the Graduate Education and Teaching Reform Project of Yanshan University, Novel Coronavirus Pneumonia Research Project of Yanshan University (Construction of Long-term Mechanism of Psychological Crisis Intervention in Novel Coronavirus Pneumonia—A Case study of Hebei Province).

REFERENCES

Abbott, N. J., Patabendige, A., Dolman, D. E. M., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25. doi: 10.1016/j.nbd.2009.07.030

Abouhussein, D. M. N., Khattab, A., Bayoumi, N. A., Mahmoud, A. F., and Sakr, T. M. (2018). Brain targeted rivastigmine mucoadhesive thermosensitive in situ gel: optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J. Drug Deliv. Sci. Technol. 43, 129–140. doi: 10.1016/j.jddt.2017.09.021

Aderibigbe, B. A., and Naki, T. (2019). Chitosan-based nanocarriers for nose to brain delivery. Appl. Sci. 9:2219. doi: 10.3390/app9112219

Akel, H., Ismail, R., and Cookea, I. (2020). Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. Eur. J. Pharm. Biopharm. 148, 38–53. doi: 10.1016/j.ejpb.2019.12.014

Alagusundaram, M., Chengaiath, B., Gnanaprakash, K., Ramkanth, S., Chetty, C. M., and Dhachinamoorthi, D. (2010). Nasal drug delivery system - an overview. Int. J. Res. Pharm. Sci. 1, 454–465.

Alam, M. I., Baboota, S., Ahuja, A., Ali, M., Ali, J., Sahni, J. K., et al. (2014). Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int. J. Pharm. 470, 99–106. doi: 10.1016/j.ijpharm.2014.05.004

Alex, A. T., Joseph, A., Shavi, G. V., Rao, J. V., and Udupa, N. (2014). Development and evaluation of carboplatin-loaded PCL nanoparticles for...
intrasinusal delivery. Drug Deliv. 23, 2144–2153. doi: 10.3109/10717544.2014.9
48643

Ambrus, R., Gieszinger, P., Gáspár, R., Sztojkov-Ivanov, A., Dúcza, E., Márki, Á., et al. (2020). Investigation of the absorption of nanosized lamotrigine containing nasal powder via the nasal cavity. Molecules 25:1065.

Angeli, E., Nguyen, T. T., Janin, A., and Bousquet, G. (2019). How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int. J. Mol. Sci. 21:22. doi: 10.3390/ijms21001002

Bachurin, S. O., Gavrilova, S. I., Samsonova, A., Barreto, G. E., and Aliev, G. (2018). Mild cognitive impairment due to Alzheimer disease: contemporary approaches to diagnostics and pharmacological intervention. Pharmacol. Res. 129, 216–226. doi: 10.1016/j.phrs.2017.11.021

Badhe, R. V., and Nipate, S. S. (2020). "Nasal bioadhesive drug delivery systems and their applications," in Biadhesive Drug Delivery, eds K. L. Mittal, I. S. Bakshi, and J. K. Narang (New Jersey, NJ: John Wiley and Sons), 259–305. doi: 10.1002/9781119460240.ch10

Bakri, W. A., Donovan, M. D., Cueto, M., Wu, Y., Orekie, C., and Yang, X. et al. Intranasal Antidepressants

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery systems. Expert Opin. Drug Deliv. 10, 908–917. doi: 10.1517/17425247.10.3.908

Bickel, J., Alves, G., Fortuna, A., and Falcao, A. (2014). Blood–brain barrier models for pharmaceutical development. Expert Opin. Biol. Ther. 3, 45–56. doi: 10.1517/14712598.3.1.45

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery systems. Expert Opin. Drug Deliv. 10, 908–917. doi: 10.1517/17425247.10.3.908

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery systems. Expert Opin. Drug Deliv. 10, 908–917. doi: 10.1517/17425247.10.3.908

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery systems. Expert Opin. Drug Deliv. 10, 908–917. doi: 10.1517/17425247.10.3.908

Bell, J. H., Hartley, P. S., and Cox, J. S. G. (1971). Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci. 60, 1559–1564. doi: 10.1002/jps.2600601028

Bento, A. P., Paulton, A. H., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., et al. (2014). The ChEMBL bioactivity database: an update. Nucleic Acids Res. 42, D1083–D1090. doi: 10.1093/nar/gkt1031

Berger, W. E., Godfrey, J. W., and Slater, A. L. (2007). Intranasal corticosteroids: a step toward improved compliance. Pharmacol. Rep. 59, 486–493. doi: 10.1517/14712598.4.6.489

Bernerki, J., Dobrowolska, A., Nierwinska, K., and Malecki, A. (2008). Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep. 60, 609–622. doi: 10.1016/j.pr.2007.12.001

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p

Bhandwalkar, M. J., and Avachat, A. M. (2013). Thermoreversible nasal drug delivery system for fluticasone furoate via nasal cavity. Biomacromolecules 20, 4258–4271. doi: 10.1021/bm301262p
and pharmacodynamic evaluation. Carbohydr. Polym. 89, 72–79. doi: 10.1016/j.carbpol.2012.02.051
Haque, H., H., Lin, D., Sun, J., He, X., Wang, T., Fang, Y., et al. (2020). An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholina toxin-like chimeric protein. J. Control. Release 322, 364–389. doi: 10.1016/j.jconrel.2017.09.001
Huang, C. H., Kimura, R., Nasser, R. B., and Hussain, A. A. (1985). Mechanism of nasal absorption of drugs I: physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J. Pharm. Sci. 74, 608–611. doi: 10.1021/jp00740a065
Inoue, D., Furubayashi, T., Tanaka, A., Sakane, T., and Sugano, K. (2020). Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats. Eur. J. Pharm. Biopharm. 149, 145–153. doi: 10.1016/j.ejpb.2020.02.004
Jadhav, K. R., Gambhire, M. N., Shaikh, I. M., Kadam, V. J., and Pisal, S. S. (2007). Drug delivery system factors affecting and applications. Curr. Drug. Ther. 2, 27–38. doi: 10.2174/17458677922374
Jiang, L., Li, S., Zheng, J., Li, Y., and Huang, H. (2019). Recent progress in microfluidic models of the blood-brain barrier. Micromachines 10:375. doi: 10.3390/10060375
Jogani, V., Shah, P., Mishra, P., Mishra, A. K., and Misra, A. (2008). Intranasal mucocutaneous microemulsion of tacrine to improve brain targeting. Alzheimers Dis. Assoc. Disord. 22, 116–124. doi: 10.1097/WAD.0b013e181357205b
Johnson, N. J., Hanson, L. R., and Frey, W. H. (2010). Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol. Pharm. 7, 884–893. doi: 10.1021/mp100029g
Khan, A. R., Liu, M., Khan, M. W., and Zhai, G. (2017). Progress in brain particulate formulations for the nasal delivery of antibodies. J. Control. Release 268, 364–389. doi: 10.1016/j.jconrel.2017.09.001
Kiyotodomo, S., Kaewmalun, S., Sritthanum, S., Surasomboon, S., and Namdee, K. (2019). The potential of mucoadhesive polymer in enhancing efficacy of direct immersion vaccination against Flavobacterium columnare infection in tilapia. Fish Shellfish Immunol. 86, 635–640. doi: 10.1016/j.fsi.2018.12.005
Krauze, M. T., Forsayeth, J., Park, J. W., and Bankiewicz, K. S. (2006). Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res. 23, 2493–2504. doi: 10.1007/s11095-006-9103-5
Kumar, A., Pandey, A. N., and Jain, S. K. (2016). Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 23, 671–683. doi: 10.3109/10717544.2014.920431
Laffleur, F., and Keckeis, V. (2020). Advances in drug delivery systems: work in progress still needed? Int. J. Pharm. 590, 109005. doi: 10.1016/j.ijpharm.2020.109005
Lechanteur, A., Neves, J., and Sarmento, B. (2017). The role of mucus in cell-based models used to screen mucosal drug delivery. Adv. Drug Deliv. Rev. 124, 50–63. doi: 10.1016/j.addr.2017.07.019
Lee, S. A., Hong, S. S., Han, X. H., Hwang, J. S., Oh, G. J., Lee, K. S., et al. (2005). Piperrine from the fruits of piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem. Pharm. Bull. 53, 832–835. doi: 10.1248/cpb.53.832
Lengyel, M., Kallaiasbzo, N., Antal, V., Laki, A. J., and Antal, I. (2019). Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci. Pharm. 87:20. doi: 10.3390/sciipharm8700020
Leong, A. D., and Stockley, P. A. (2015). The relationship between nasal anatomy and human olfaction. Laryngoscope 98, 1232–1238. doi: 10.1002/lary.23734
Li, L., Nandi, I., and Kim, K. H. (2002). Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diapizem. Int. J. Pharm. 237, 77–85. doi: 10.1016/S0378-5173(02)00029-7
Li, S., Zhang, T., Xu, W., Ding, J., Yin, F., Xu, J., et al. (2018). Sarcoma-targeting peptide-polyester nanoparticle intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics 8, 1361–1375. doi: 10.7150/thno.18299
Li, Y., Fan, X., Li, W., Yang, P., Zhang, H., Tang, D., et al. (2018). Metoclopromamide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Pharm. Dev. Technol. 23, 275–281. doi: 10.1080/10717544.2017.1316734
Loirapotorizia, C., Todoroff, J., and Vanrever, R. (2014). Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev. 75, 81–91. doi: 10.1016/j.addr.2014.05.017
Maculotti, K., Genta, I., Perugini, P., Imam, M., Berkon-Schnürch, A., and Pavanello, F. (2005). Preparation and in vitro evaluation of thiolated chitosan microparticles. J. Microencapsul. 22, 459–470. doi: 10.1080/02652040500162220
Mansuri, S., Kesarwani, P., Jain, K., Tekade, R. K., and Jain, N. K. (2016). Mucoadhesion: a promising approach in drug delivery system. React. Funct. Polym. 100, 151–172. doi: 10.1016/j.reactfunctpolymer.2016.01.011
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., et al. (2003). Metabolism, excretion, and pharmacokinetics...
Qian, S., Wong, Y. C., and Zuo, Z. (2014). Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int. J. Pharm. 468, 272–282. doi: 10.1016/j.ijpharm.2014.04.015

Qu, H., Guo, H., Li, D., Hou, Y., Kuang, T., and Ding, J. (2020). Intravesical hydrogels as drug reservoirs. Trends Biotechnol. 38, 579–583. doi: 10.1016/j.tibtech.2019.10.012

Qinanta, D. S., Westlye, L. T., Rustan, Ø. G., Tesli, N., Poppy, C. L., Smievik, H., et al. (2015). Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl. Psychiatry 5:e602. doi: 10.1038/tp.2015.93

Rohm, M., Carle, S., Maigler, F., Flamm, J., Kramer, V., Mavoungou, C., et al. (2017). A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. Int. J. Pharm. 532, 537–546. doi: 10.1016/j.ijpharm.2017.09.027

Rohrer, J., Lups, N., and Berzokpschnurch, A. (2018). Advanced formulations for intranasal delivery of biologics. Int. J. Pharm. 553, 8–20. doi: 10.1016/j.ijpharm.2018.10.029

Sabir, F., Ismail, R., and Cooaka, I. (2020). Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov. Today 25, 185–194. doi: 10.1016/j.drudis.2019.10.005

Saeedi, M., Eslamifar, M., Khezri, K., and Dizaj, S. M. (2019). Applications of nanotechnology in drug delivery to the central nervous system. Biomed. Pharmacother. 111, 666–675. doi: 10.1016/j.biopha.2018.12.133

Salade, L., Wauthoz, N., Goole, J., and Amighi, K. (2019). How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int. J. Pharm. 561, 47–65. doi: 10.1016/j.ijpharm.2019.02.026

Sharma, A., and Sharma, U. S. (1997). Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154, 123–140. doi: 10.1016/S0378-5173(97)00135-X

Sharma, G., Mishra, A. K., Mishra, P., and Misra, A. (2009). Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech 10, 1321–1330. doi: 10.1208/s12249-009-9329-9

Shetty, N., Cipolla, D., Park, H., and Zhou, Q. T. (2020). Physical stability of dry powder inhaler formulations. Expert Opin. Drug Deliv. 17, 77–96. doi: 10.1080/17448069.2020.1702643

Shi, X., Miao, W., Pang, D., Wu, I., Tong, Q., Li, J., et al. (2020). Angiopex-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. Biomater. Sci. 8, 1290–1297. doi: 10.1039/C9MB01750J

Sindhu, P., Kumar, S., Iqbal, B., Ali, J., and Babootta, S. (2018). Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. J. Psychiatr. Res. 99, 83–95. doi: 10.1016/j.jpsychires.2018.01.015

Singh, D. N., Rashid, M., Hallan, S. S., Mehta, N. K., Prakash, A., and Mishra, N. (2015). Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif. Cells Nanomed. Biotechnol. 44, 865–877. doi: 10.3109/21691401.2014.998824

Singh, R. M. P., Kumar, A., and Pathak, K. (2013). Thermally triggered mucoadhesive in situ gel of loratadene: β-cyclodextrin complex for nasal delivery. AAPS PharmSciTech 14, 412–424 doi: 10.1208/s12249-013-9921-9

Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., et al. (2017). Nanoemulsion: Concepts, development and applications in drug delivery. J. Control. Release 252, 28–49. doi: 10.1016/j.jconrel.2017.03.008

Sintov, A., Levy, H. V., and Botner, S. (2010). Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies. J. Control. Release 148, 168–176. doi: 10.1016/j.jconrel.2010.08.004

Sun, C., Ding, Y., Zhou, L., Shi, D., Sun, L., Webster, T. J., et al. (2017). Noninvasive nanoparticle strategies for brain tumor targeting. Nanomedicine 13, 2605–2621. doi: 10.2217/nnm.17.007

Taipaleenmäki, E., and Stadler, B. (2020). Recent advancements in using polymers for intestinal mucosal adhesion and mucopenetration. Macromol. Biosci. 20:1900342. doi: 10.1002/mabi.201900342

Talegaonkar, S., and Mishra, P. R. (2004). Intranasal delivery: an approach to bypass the blood brain barrier. Indian J. Pharmocol. 36, 140–147.
Tang, F., Hartz, A. M. S., and Bauer, B. (2017). Drug-resistant epilepsy: multiple hypotheses, few answers. Front. Neurol. 8: 301. doi: 10.3389/fneur.2017.00301
Thakkar, H., Patel, A. A., and Chauhan, N. P. (2013). Intranasal mucoadhesive microemulsion of mirtazapine: pharmacokinetic and pharmacodynamic studies. Asian J. Pharm. 7:36. doi: 10.4103/0973-8398.110934
Thorne, R. G., and Frey, W. H. (2001). Delivery of neurotrophic factors to the central nervous system. Clin. Pharmacokinet 40, 907–946. doi: 10.2165/00003088-200140120-00003
Thorne, R. G., Pronk, G. J., Padmanabhan, V., and Frey, W. H. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481–496. doi: 10.1016/j.neuroscience.2004.05.029
Tong, G., Qin, N., and Sun, L. (2017). Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. J. Saudi Pharm. Soc. 25, 844–851. doi: 10.1016/j.jsps.2016.12.003
Trangsrud, A. J., Whitaker, A. L., and Small, R. E. (2002). Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 22, 1458–1467. doi: 10.1592/phco.22.16.1458.33692
Ugwoke, M. I., Sam, E., van Den Mooter, G., Verbeke, N., and Kinget, R. (1999). Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int. J. Pharm. 181, 125–138. doi: 10.1016/S0378-5173(99)00018-6
Venereau, E., de Leo, F., Mezzapelle, R., Carecchia, G., Musco, G., and Bianchi, M. E. (2016). HMGB1 as biomarker and drug target. Pharmacol. Res. 111, 534–544. doi: 10.1016/j.phrs.2016.06.031
Vitorino, C., Silva, S., Bicker, J., Falcão, A., and Fortuna, A. (2019). Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discov. Today 24, 1911–1923. doi: 10.1016/j.drudis.2019.06.001
Villasaliv, D., Exposito-Harris, R., Heras, A., Casettari, L., Garnett, M., Illum, L., et al. (2010). Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 400, 183–193. doi: 10.1016/j.ijpharm.2010.08.020
Vyas, T. K., Babbar, A. K., Sharma, R. K., and Misra, A. (2005). Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J. Drug Target. 13, 317–324. doi: 10.1080/10611860500246217
Vyas, T. K., Babbar, A. K., Sharma, R. K., Singh, S., and Misra, A. (2006a). Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech 7, E49–E57. doi: 10.1208/pst070108
Vyas, T. K., Babbar, A. K., Sharma, R. K., Singh, S., and Misra, A. (2006b). Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci. 95, 570–580. doi: 10.1002/jps.20480
Wang, S., Sun, Y., Zhang, J., Cui, X., Xu, Z., Ding, D., et al. (2020). Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics. Front. Pharmacol. 11:230. doi: 10.3389/fphar.2020.00230
Wang, W., Sun, C., Mao, L., Ma, P., Liu, F., Yang, J., et al. (2016). The biological activities, chemical stability, metabolism and delivery systems of quercetin: a review. Trends Food Sci. Technol. 56, 21–38. doi: 10.1016/j.tifs.2016.07.004
Wang, Z., and Chow, M. S. (2014). Overview and appraisal of the current concept and technologies for improvement of sublingual drug delivery. Ther. Deliv. 5, 807–816. doi: 10.4155/tde.14.50
Wong, C. Y., Alsalami, H., and Dass, C. R. (2017). Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J. Control. Release 264, 247–275. doi: 10.1016/j.jconrel.2017.09.003
Yamamoto, Y., Danhof, M. M., and de Lange, E. C. (2017). Microdialysis: the key to physiologically based model prediction of human CNS target site concentrations. AAPS J. 19, 891–909. doi: 10.1208/s12248-017-0050-3
Zhang, M., Zhang, X., Wang, M., Li, Z., Qiao, M., Hu, H., et al. (2019). Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J. Mater. Chem. B 7, 2421–2433. doi: 10.1039/C9TB00170K
Zhang, Q., Jiang, X., Jiang, W., Lu, W., Su, L., and Shi, Z. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 275, 85–96. doi: 10.1016/j.ijpharm.2004.01.039
Zhang, Y., Yu, J., Ren, K., Zuo, J., Ding, J., and Chen, X. (2019). Thermosensitive hydrogels as scaffolds for cartilage tissue engineering. Biomacromolecules 20, 1478–1492. doi: 10.1021/acs.biomac.9b00043

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Xu, Tao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.